Source: Andrew Wynn
William Blair’s Updated Rating For Sarepta Therapeutics
William Blair, a well-respected global investment banking and management firm, recently revised its rating for Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leading biotechnology company. On July 17, 2025, Blair updated its grade for NASDAQ:SRPT to “Market Perform,” maintaining a “hold” action. This update reflects the firm’s neutral stance on the company’s stock, suggesting that it expects the stock to perform in line with the broader market.
The updated rating came at a time when the stock price was approximately $21.98. This price represents a significant increase for Sarepta, which has been making notable strides in the biotechnology sector. The company’s stock price has seen a rise following updates regarding its innovative gene therapy, Elevidys.
Sarepta Therapeutics Undergoing Strategic Reorganization
The William Blair rating update came as Sarepta was in the midst of a strategic reorganization. The company is undertaking these changes to strengthen its position in the competitive biotechnology sector. The focus of this reorganization is gene therapy for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration and weakness.
Sarepta’s reorganization strategy has bolstered investor confidence in its potential for future growth. The company’s innovative approach to treating DMD has set it apart from competitors like Pfizer and Roche, which are also working on DMD treatments.
Sarepta’s Gene Therapy, Elevidys
The gene therapy Elevidys is a flagship product of Sarepta. The company is working diligently to expand the label for Elevidys. This expansion aims to broaden the range of conditions the therapy can treat, potentially increasing its market share and profitability.
However, the Food and Drug Administration (FDA) has requested a black box warning for Elevidys, relating to the risks of acute liver injury and failure. A black box warning is the FDA’s most stringent warning for prescription drugs, often indicating serious or life-threatening risks. Sarepta has agreed to this change, which shows its commitment to patient safety and regulatory compliance.
Sarepta’s Response to FDA’s Black Box Warning Request
In response to the FDA’s request, Sarepta temporarily halted shipments of Elevidys for non-ambulatory patients. The company established a committee to review cases of acute liver failure linked to the therapy. This committee is considering additional immunosuppression regimens to mitigate these risks.
The company has agreed on an enhanced regimen using sirolimus, a drug used to prevent organ rejection in transplant patients, for non-ambulant patients. Sarepta intends to submit these findings to the FDA for further discussion. The outcome of these discussions could significantly impact the company’s future stock performance.
Sarepta’s Stock Performance
At present, NASDAQ:SRPT is priced at $21.98, reflecting a 19.59% increase with a change of $3.60. The stock has fluctuated between $20.94 and $22.86 today. Over the past year, it reached a high of $153.30 and a low of $16.88. With a market capitalization of approximately $2.16 billion and a trading volume of 19,634,197 shares, Sarepta Therapeutics remains a significant player on the NASDAQ exchange.
In conclusion, Sarepta Therapeutics’ strategic reorganization, coupled with its commitment to patient safety and regulatory compliance, has bolstered investor confidence. The company’s innovative gene therapy products and focused approach to treating rare diseases like DMD continue to set it apart in the biotechnology sector.